You are here

  • Home
  • Archive
  • Volume 68, Issue 3
  • Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation

Article Text

Article menu
Download PDFPDF
Letter
Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation
  1. J C Henes1,
  2. F Heinzelmann2,
  3. A Wacker1,
  4. H P Seelig4,
  5. R Klein1,
  6. A Bornemann3,
  7. C Faul1,
  8. L Kanz1,
  9. I Koetter1
  1. 1
    Department of Internal Medicine II (Oncology, Haematology, Immunology, Rheumatology, Pulmology), University Hospital, Tuebingen, Germany
  2. 2
    Department of Radiooncology, University Hospital, Tuebingen, Germany
  3. 3
    Department of Neuropathology, University Hospital, Tuebingen, Germany
  4. 4
    Private Laboratories Seelig, Karlsruhe, Germany
  1. Professor I Koetter, University Hospital, Department of Internal Medicine II, Otfried-Mueller-Strasse 10, D-72076 Tuebingen, Germany; ina.koetter{at}med.uni-tuebingen.de

https://doi.org/10.1136/ard.2008.094755

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Patients with antisignal recognition particle (SRP)-positive myositis usually present with symmetric, progressive muscle weakness and highly elevated levels of serum creatine phosphokinase (CPK).1

    A 32-year-old male patient presented with these symptoms (CPK 3601 U/l, normal range 0–190 U/l) in September 2000. Magnetic resonance imaging (MRI) of the thighs revealed a massive oedema (fig 1). After ineffective treatment with glucocorticosteroids, azathioprine, methotrexate, ciclosporine A, mycophenolate mofetil and intravenous immunoglobulins MRI assessed active myositis. The muscle biopsy revealed a necrotising myopathy. Treatment was switched to cyclophosphamide pulses with 750 mg/m2 every 3 weeks and intensified by high-dose cyclophosphamide for stem cell mobilisation with 4000 …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Patient consent: Obtained.